Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren/HCTZ vs Aliskiren in Stage II Hypertension
NCT00705575Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2008
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of aliskiren in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Change in Mean Sitting Systolic Blood Pressure From Baseline to End of Study (Week 12). Started Jun 2008; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00705575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705575.